R&D
Rooted in distinctive platform technology based on strong medicinal chemistry expertise, LCB is a global biotechnology company dedicated to drug discovery and development
Core Technology
ConjuALLTM
Next Generation ADC platform
Conjugation Method
- Achieving high-purity homogeneous ADC through specific site conjugation.
- Plasma stable linker enabling cancer specific toxin release
- Excellent PK profile through minimal antibody modification viaproprietary conjugation and linker chemistry.
LCB’s β-Glucuronide Linker
Tumor selective payload release via β-Glucuronidase cleavage enhances safety and efficacy- Plasma-stable and tumor-labile
- Mitigates off-target and on-target toxicity via highly selective cleavage by cancer-specific enzymes
- Allows for bystander effect, Immunogenic Cell Death, etc.
- Compatible across payload classes
Cytotoxic Payload
Payload toolbox
- 1Cytotoxic payload
- Microtubule inhibitor
- Topo 1 Inhibitor
- Novel Toxin : PBD prodrug, New Topo1
- 2Immune modulation payload
- Novel STING agonist
LCB's payload strategy
- 1Prodrug approach*
: PBD prodrug, ...
- 2Immune agonist approach**
: Novel Sting-agonist, ...
- 3TPD (Targeted Protein Degrader)
: Molecular Glue, ...
- 4Hybrid approach
: Dual payload (Cytotoxic + Cytotoxic, Cytotoxic + Immune-agonist, ...)
* Prodrug approach
Immunomodulator
Next Generation STING agonist- Improved PK and reduced toxicity
- Maximized potency in tumor tissue
- Induced anti-cancer immunity
